Accordingly, in this scenario, the tumor-derived cDC1 primes CD8 T cells while tumor-derived cDC2 activates CD4 T cells in the first step of the CTL priming process and then in the second step, the activated CD4 T cells licenses a LN-resident cDC1 to relay the help for CTLs. Here, MPPE1 is linked to neoplasm.